Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Product sales, net	$ 2,700,902	$ 2,924,707
Cost of products sold	1,018,476	1,122,413
Gross profit	1,682,426	1,802,294
Selling, general and administrative expenses	3,115,629	2,749,299
Research and development expenses	464,466	16,444
Depreciation and amortization expense	16,814	20,924
Total operating expenses	3,596,909	2,786,667
Loss from operations	(1,914,483)	(984,373)
Interest expense, net	(4,742)	(2,535)
Loss before provision for income taxes and net of equity investments	(1,919,225)	(986,908)
Provision for income taxes	0	(250)
Loss before equity investment	(1,919,225)	(987,158)
Deferred profit and divesture-equity investment (See Note 6)	0	1,301
Net loss	(1,919,225)	(985,857)
Net loss attributable to noncontrolling interests	(17,502)	(12,988)
Net loss attributable to Milestone Scientific Inc.	$ (1,901,723)	$ (972,869)
Net loss per share applicable to common stockholders—
Basic (in dollars per share)	$ (0.03)	$ (0.01)
Diluted (in dollars per share)	$ (0.03)	$ (0.01)
Weighted average shares outstanding and to be issued—
Basic (in shares)	69,013,001	66,578,435
Diluted (in shares)	69,013,001	66,578,435